Company
Prothena Corporation
NASDAQ:PRTA
Prothena Corporation plc is a global, clinical biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of progressive, life-threatening diseases associated with this biology. Prothena's pipeline of antibody therapeutic candidates targets a number of indications including Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues to advance additional discovery programs against targets including tau, Aβ (Amyloid beta) and ALECT2 where its deep scientific understanding of disease pathology can be leveraged.
3 stories
Woodford-backed Prothena collapses as it scraps development of lead drug after mid-stage trial failure
NEOD001 was being developed to treat a rare disease called AL amyloidosis, but it missed both its primary and secondary endpoints in a Phase IIb trial and Prothena has decided to scrap its development altogether
Prothena shares collapse as it scraps development of lead drug after mid-stage trial failure
NEOD001 was being developed to treat a rare disease called AL amyloidosis, but it missed both its primary and secondary endpoints in a Phase IIb trial and Prothena has decided to scrap its development altogether